Minocycline 40 mg outperforms doxycycline for rosacea in meta-analysisMinocycline Shows Better Success Rates for Treating Rosacea

Clinical and experimental dermatology Published September 25, 2026 Study authors: Ghanem Laura, Gutu Cristina Sicorschi, Mendoza-Millán Daniela Lucía, Monteiro Leitão Neto Carlos Alb… PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Minocycline 40 mg extended-release beat doxycycline for rosacea treatment success in a meta-analysis of 643 patients.

A meta-analysis of 643 patients with rosacea compared minocycline hydrochloride 40 mg extended-release capsules (DFD-29) against modified-release doxycycline. The primary outcome was Investigator Global Assessment treatment success (IGA-TS).

DFD-29 significantly increased the likelihood of achieving successful IGA-TS compared with doxycycline (OR 2.51; 95% CI 1.80–3.49; P < 0.001). The 40 mg group also had significantly greater reductions in IGA-TS scores than the 20 mg group (P = 0.02).

For inflammatory lesion counts, the 40 mg group showed a significantly greater reduction than doxycycline (mean difference -4.56; 95% CI -6.18 to -2.93; P < 0.001), while the 20 mg group showed no significant reduction.

Safety analyses found no significant differences in treatment-emergent adverse events across groups. One serious adverse event (atrial fibrillation) was reported with DFD-29. Tolerability was described as well-tolerated.

Limitations were not reported, and the meta-analysis is based on only three randomized controlled trials. Funding and conflicts of interest were not reported. DFD-29 at 40 mg daily appears to be a superior, well-tolerated alternative to modified-release doxycycline for moderate-to-severe rosacea.

How this fits prior evidence

This meta-analysis addresses a gap in the comparative efficacy of specific minocycline formulations for rosacea. While prior coverage established doxycycline as a supported treatment for infectious syphilis and a means to reduce Wolbachia burden in bancroftian filariasis, this study specifically evaluates DFD-29 as a superior alternative to modified-release doxycycline for moderate-to-severe rosacea. The finding of a significantly higher likelihood of success (OR 2.51) for DFD-29 compared to doxycycline provides specific evidence for this clinical scenario.

A meta-analysis of three randomized controlled trials looked at how different medications treat rosacea. The study compared minocycline hydrochloride 40 mg extended-release capsules (DFD-29) against modified-release doxycycline in 643 patients. The goal was to see which treatment better reduced skin inflammation and improved overall scores.

The results showed that the 40 mg dose of minocycline significantly increased the likelihood of a successful treatment score compared to doxycycline. Additionally, the 40 mg minocycline group saw a greater reduction in inflammatory lesion counts than the doxycycline group. The 20 mg dose of minocycline did not show a significant reduction in these lesions.

Safety data showed that the minocycline was well-tolerated with no significant differences in common side effects between the groups. One serious heart-related event was reported in the minocycline group. Because this analysis was based on only three trials, the results should be viewed as preliminary. Talk to your doctor to see if this specific medication is a suitable option for your skin condition.

What this means for you:

Minocycline 40 mg may be more effective than doxycycline for reducing inflammatory lesions in rosacea patients.

Common questions

Is minocycline more effective than doxycycline for rosacea?

The study found that minocycline 40 mg extended-release capsules significantly increased the likelihood of achieving a successful treatment score compared to doxycycline. The 40 mg minocycline group also showed a significantly greater reduction in inflammatory lesion counts than the doxycycline group.

Are there side effects to the minocycline treatment?

The minocycline was reported to be well-tolerated, with no significant differences in common adverse events between the groups. However, one serious adverse event involving atrial fibrillation was reported in the minocycline group.

Does the 20 mg dose of minocycline work as well as the 40 mg dose?

No, the results showed that the 40 mg minocycline group had significantly greater reductions in scores and inflammatory lesions compared to the 20 mg group. The 20 mg group showed no significant reduction in inflammatory lesion counts.

Study Details

Study typeMeta analysis

Sample sizen = 643

EvidenceLevel 1

PublishedSep 2026

PMID41802266

View Original Abstract ↓

BACKGROUND: Rosacea is a chronic skin disorder characterized by facial erythema, telangiectasias, papules and pustules. Guidelines recommend subantimicrobial doses of drugs such as doxycycline 40 mg. In patients with persistent symptoms, evaluating the efficacy and safety of subantimicrobial doses of minocycline may expand treatment options. OBJECTIVES: To evaluate minocycline hydrochloride 40 mg extended-release capsules (formerly known as and hereafter referred to as DFD-29) as a low-dose tetracycline alternative to treat rosacea. METHODS: Our analysis included data from three randomized controlled trials sourced from the PubMed, Embase and Cochrane databases to compare Investigator Global Assessment treatment success (IGA-TS) scores, reduction in inflammatory lesion counts, treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients using DFD-29 vs. modified-release doxycycline. Statistical analyses were conducted using RStudio. RESULTS: In a pooled analysis of 643 patients, DFD-29 significantly increased the likelihood of achieving a successful IGA-TS score compared with doxycycline [odds ratio (OR) 2.51, 95% confidence interval (CI) 1.80-3.49; P < 0.001; I2 = 0%]. The DFD-29 40 mg group had significantly greater reductions in IGA-TS scores compared with the DFD-29 20 mg group (P = 0.02). The DFD-29 40 mg group also exhibited a significantly greater reduction in inflammatory lesion counts than the doxycycline group (mean difference -4.56, 95% CI -6.18 to -2.93; P < 0.001), whereas the DFD-29 20 mg group showed no significant reduction. There were no significant differences in TEAEs across groups (OR 0.96, 95% CI 0.55-1.66; P = 0.87; I2 = 0%), with just one SAE (atrial fibrillation) reported with DFD-29. CONCLUSIONS: Our meta-analysis showed that DFD-29 at 40 mg daily is a superior, well-tolerated alternative to modified-release doxycycline for moderate-to-severe rosacea.

Minocycline 40 mg outperforms doxycycline for rosacea in meta-analysisMinocycline Shows Better Success Rates for Treating Rosacea

How this fits prior evidence

Common questions

Study Details

Candidiasis prevalence of 13.46% and Cryptococcal meningitis of 3.15% among HIV-positive individuals

New data shows prevalence of fungal infections in HIV patients

Clinical research that matters. Delivered to your inbox.

Minocycline 40 mg outperforms doxycycline for rosacea in meta-analysisMinocycline Shows Better Success Rates for Treating Rosacea

How this fits prior evidence

Common questions

More on Rosacea

Study Details

Candidiasis prevalence of 13.46% and Cryptococcal meningitis of 3.15% among HIV-positive individuals

New data shows prevalence of fungal infections in HIV patients

Clinical research that matters. Delivered to your inbox.

Related in Infectious Disease

From Other Specialties